RHHBY News and Press, Roche Holding Ltd ADR From 02/26/26

2026-02-26 13:35:52 ET More on leading drugmakers Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade) Merck: Why Investors Should Remain Bullish Despite Patent Risks ...

2026-02-26 08:33:12 ET More on Roche Holding, Ryanair Holdings, etc. Nu Holdings: Great Business At An Expensive Price Nu Holdings Ltd. (NU) Q4 2025 Earnings Call Transcript Nu Holdings Ltd. 2025 Q4 - Results - Earnings Call Presentation argenx SE GAAP EPS of...

2026-02-25 11:42:41 ET More on Recursion Pharmaceuticals Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript Recursion Pharmaceuticals: Stock Unresponsive To Clinical Updates Recursion Pharmaceuticals, Inc. (RXRX) Prese...

2026-02-23 13:06:13 ET Read the full article on Seeking Alpha For further details see: Here are the quant ratings of OZEM’s top holdings amid Novo's selloff

2026-02-20 15:21:00 ET More on pharmaceutical companies Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades) Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects Pfizer: Recovery Isn't Over, Battered Valuation St...

2026-02-20 08:54:31 ET More on Roche Roche Holding AG (RHHBY) Shareholder/Analyst Presentation Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript Oakmark Global Concentrated Strategy adds SNY...

– First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment – – Approval expands Genentech’s fixed-duration portfolio by providing eligible first-line patients another option alongside t...

– Filing acceptance based on Phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard-of-care endocrine therapy plus everolimus – – Strength o...

2026-02-19 13:31:04 ET More on AbbVie, AstraZeneca PLC, etc. Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game Pfizer: The Rebound Looks Unsustainable AbbVie: Dominating Immunology While Building Oncology Upside Merck posts n...

2026-02-19 12:44:15 ET More on Sanofi, Mercedes-Benz Group AG, etc. Mercedes-Benz Group AG (BENZ:CA) Q4 2025 Earnings Call Prepared Remarks Transcript Mercedes-Benz Group AG 2025 Q4 - Results - Earnings Call Presentation Sanofi: CEO Leaves With Project Rejuvenation U...